Other potential therapies involve the ERα antagonist fulvestrant (ICI182.780), which has demonstrated some clinical effects in female lupus patients by preventing estrogen–ERα signalling in pDCs [209] and may also be beneficial in a subset of asthma patients. Here, ESR1 is linked to systemic lupus erythematosus.